A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs Autologous-non-bulbar-dermal-sheath-fibroblast-therapy-RepliCel-Life-Sciences (Primary)
  • Indications Tendon injuries
  • Focus Adverse reactions
  • Acronyms ReaCT
  • Sponsors RepliCel Life Sciences
  • Most Recent Events

    • 28 Mar 2017 Results published in a RepliCel Life Sciences media release.
    • 05 Jan 2017 According to a RepliCel Life Sciences media release, data from this trial is expected mid-way through Q1 2017.
    • 11 Aug 2016 According to a RepliCel Life Sciences media release, the final injection is given in this trial of RCT-01 for treating patients with chronic achilles tendinopathy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top